Key Points
- CEO Anhco Nguyen sold 5,062 shares of Atara Biotherapeutics at an average price of $8.08, totaling $40,900.96. The sale covered tax-withholding obligations tied to vested equity awards, leaving Nguyen with 132,775 shares.
- Atara reported a quarterly loss of $0.32 per share, in line with estimates, while revenue of $0.63 million exceeded expectations of $0.55 million. The company remains deeply unprofitable, with a negative net margin of 269.42%.
- Analyst sentiment is mixed but averages to a “Moderate Buy”, with a consensus price target of $9.50. Institutional investors own approximately 70.9% of the company’s stock.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CEO Anhco Nguyen sold 5,062 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $8.08, for a total transaction of $40,900.96. Following the completion of the transaction, the chief executive officer owned 132,775 shares of the company's stock, valued at approximately $1,072,822. This represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Atara Biotherapeutics Stock Performance
Shares of NASDAQ ATRA opened at $9.38 on Thursday. The company has a market capitalization of $94.18 million, a PE ratio of -7.95 and a beta of 0.12. The company's fifty day moving average price is $9.30 and its 200 day moving average price is $7.54. Atara Biotherapeutics, Inc. has a 1 year low of $3.92 and a 1 year high of $19.15.
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.32). The company had revenue of $0.63 million during the quarter, compared to analysts' expectations of $0.55 million. Atara Biotherapeutics had a negative net margin of 269.42% and a negative return on equity of 79.12%. On average, equities analysts expect that Atara Biotherapeutics, Inc. will post -0.16 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATRA. Globeflex Capital L P raised its holdings in shares of Atara Biotherapeutics by 399.6% during the 4th quarter. Globeflex Capital L P now owns 77,224 shares of the biotechnology company's stock worth $1,397,000 after acquiring an additional 61,766 shares during the period. Marshall Wace LLP acquired a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at about $327,000. Mackenzie Financial Corp grew its holdings in shares of Atara Biotherapeutics by 183.5% in the third quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company's stock valued at $914,000 after purchasing an additional 41,302 shares during the period. Bridgeway Capital Management LLC grew its holdings in shares of Atara Biotherapeutics by 133.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company's stock valued at $591,000 after purchasing an additional 18,691 shares during the period. Finally, Vanguard Group Inc. increased its position in Atara Biotherapeutics by 6.6% during the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company's stock worth $2,915,000 after purchasing an additional 12,677 shares during the last quarter. Hedge funds and other institutional investors own 70.90% of the company's stock.
Analyst Ratings Changes
Several brokerages recently weighed in on ATRA. TD Cowen upgraded Atara Biotherapeutics to a "strong-buy" rating in a research note on Monday. Canaccord Genuity Group set a $13.00 price target on Atara Biotherapeutics and gave the stock a "buy" rating in a research report on Friday, May 8th. Freedom Capital raised Atara Biotherapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, May 18th. Wall Street Zen raised shares of Atara Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, August 16th. Finally, Weiss Ratings upgraded Atara Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $9.50.
Get Our Latest Stock Analysis on Atara Biotherapeutics
Atara Biotherapeutics Company Profile
(
Get Free Report)
Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company's lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
